[Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch].
BACKGROUND: Type I allergy represents a severe health problem in industrialized countries where up to 20% of the population suffers from allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis, leading to death. OBJECTIVE: The aim of this study was to e...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | German |
| Published: |
1996
|
| _version_ | 1797093717537980416 |
|---|---|
| author | Menz, G Dolecek, C Schönheit-Kenn, U Ferreira, F Moser, M Schneider, T Suter, M Boltz-Nitulescu, G Ebner, C Kraft, D Valenta, R |
| author_facet | Menz, G Dolecek, C Schönheit-Kenn, U Ferreira, F Moser, M Schneider, T Suter, M Boltz-Nitulescu, G Ebner, C Kraft, D Valenta, R |
| author_sort | Menz, G |
| collection | OXFORD |
| description | BACKGROUND: Type I allergy represents a severe health problem in industrialized countries where up to 20% of the population suffers from allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis, leading to death. OBJECTIVE: The aim of this study was to evaluate recombinant Bet v 1, the major birch pollen allergen for in vivo and in vitro diagnosis of birch pollen allergy. METHODS: A group of 51 birch pollen allergic patients and eight non-allergic control individuals were tested for birch pollen allergy by skin-prick and intradermal testing, comparing commercial birch pollen extracts with recombinant Bet v 1. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and immunoblotting. RESULTS: Recombinant Bet v 1 allowed accurate in vivo and in vitro diagnosis of tree pollen allergy in 49/51 patients tested. No false positive results were obtained in any in vitro assay system (ELISA, Westernblot) or by skin testing (skin-prick, intradermal test) with recombinant Bet v 1. CONCLUSION: Our results document that recombinant Bet v 1 produced in bacterial expression systems allows accurate in vitro and in vivo diagnosis of birch pollen allergy in > 95% of birch pollen allergic patients. |
| first_indexed | 2024-03-07T04:04:16Z |
| format | Journal article |
| id | oxford-uuid:c59bcc7b-da3f-447d-85c5-18dda009141c |
| institution | University of Oxford |
| language | German |
| last_indexed | 2024-03-07T04:04:16Z |
| publishDate | 1996 |
| record_format | dspace |
| spelling | oxford-uuid:c59bcc7b-da3f-447d-85c5-18dda009141c2022-03-27T06:32:13Z[Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch].Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c59bcc7b-da3f-447d-85c5-18dda009141cGermanSymplectic Elements at Oxford1996Menz, GDolecek, CSchönheit-Kenn, UFerreira, FMoser, MSchneider, TSuter, MBoltz-Nitulescu, GEbner, CKraft, DValenta, R BACKGROUND: Type I allergy represents a severe health problem in industrialized countries where up to 20% of the population suffers from allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis, leading to death. OBJECTIVE: The aim of this study was to evaluate recombinant Bet v 1, the major birch pollen allergen for in vivo and in vitro diagnosis of birch pollen allergy. METHODS: A group of 51 birch pollen allergic patients and eight non-allergic control individuals were tested for birch pollen allergy by skin-prick and intradermal testing, comparing commercial birch pollen extracts with recombinant Bet v 1. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and immunoblotting. RESULTS: Recombinant Bet v 1 allowed accurate in vivo and in vitro diagnosis of tree pollen allergy in 49/51 patients tested. No false positive results were obtained in any in vitro assay system (ELISA, Westernblot) or by skin testing (skin-prick, intradermal test) with recombinant Bet v 1. CONCLUSION: Our results document that recombinant Bet v 1 produced in bacterial expression systems allows accurate in vitro and in vivo diagnosis of birch pollen allergy in > 95% of birch pollen allergic patients. |
| spellingShingle | Menz, G Dolecek, C Schönheit-Kenn, U Ferreira, F Moser, M Schneider, T Suter, M Boltz-Nitulescu, G Ebner, C Kraft, D Valenta, R [Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch]. |
| title | [Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch]. |
| title_full | [Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch]. |
| title_fullStr | [Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch]. |
| title_full_unstemmed | [Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch]. |
| title_short | [Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch]. |
| title_sort | serologic and skin test diagnosis of birch pollen allergy with recombinant bet v 1 the chief allergen of birch |
| work_keys_str_mv | AT menzg serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch AT dolecekc serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch AT schonheitkennu serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch AT ferreiraf serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch AT moserm serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch AT schneidert serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch AT suterm serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch AT boltznitulescug serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch AT ebnerc serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch AT kraftd serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch AT valentar serologicandskintestdiagnosisofbirchpollenallergywithrecombinantbetv1thechiefallergenofbirch |